ArticleInsights into imaging2022
Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma.
Article in Insights into imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
MUK Nine b: OPTIMUM. A Phase II Study Evaluating Optimised Combination of Biological Therapy in Newly Diagnosed High Risk Multiple Myeloma and Plasma Cell Leukaemia.
AI Technologies for Enhanced and Celerated High-Field WB-MRI
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Whole-body MRI for staging and follow-up of primary musculoskeletal tumours: a systematic review.The British journal of radiology · 2026Pooled it
- AI-derived whole-body MRI metrics in patients with multiple myeloma reveal unique insights into body composition and outcomes.Blood advances · 2026Observational
- Fifteen years of use of functional imaging in multiple myeloma: where we started and where we are going.Blood advances · 2025Review
- Qualitative and Quantitative Inter-Observer Agreement of Multiparametric Whole-Body MRI in Staging and Follow-Up of Myeloma Patients.Diagnostics (Basel, Switzerland) · 2025Article
- Functional personalized complex combination nano therapy for osteosarcoma.Scientific reports · 2025Article
- An open-source repository-based tool for quality control of imaging protocol compliance: demonstration in a multicentre MRI study.The British journal of radiology · 2025Article
- ADC measurement in whole-body MRI for multiple myeloma: a three b-values vs. two b-values DWI comparison.La Radiologia medica · 2025Article
- Whole body MRI by MY-RADS for imaging response assessment in multiple myeloma.Blood cancer journal · 2025Observational
- Review
- When advanced MRI is not about naming musculoskeletal lesions.The British journal of radiology · 2024Review
- Review
- Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.BMC cancer · 2024Article
- The role of gadolinium-based contrast agents in magnetic resonance imaging structured reporting and data systems (RADS).Magma (New York, N.Y.) · 2024Review
- Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma study.Insights into imaging · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 13 institutions in 1 country.
Funding
Abstract
backgroundWhole-body (WB) MRI, which includes diffusion-weighted imaging (DWI) and T
methodsThe standardised MY-RADS WB-MRI protocol was set up on a local 1.5 T scanner. An imaging manual describing the MR protocol, quality assurance/control procedures and data transfer was produced and provided to sites. For non-identical scanners (different vendor or magnet strength), site visits from our physics team were organised to support protocol optimisation. The site qualification process included review of phantom and volunteer data acquired at each site and a teleconference to brief the multidisciplinary team. Image quality of initial patients at each site was assessed.
resultsWB-MRI was successfully set up at 12 UK sites involving 3 vendor systems and two field strengths. Four main protocols (1.5 T Siemens, 3 T Siemens, 1.5 T Philips and 3 T GE scanners) were generated. Scanner limitations (hardware and software) and scanning time constraint required protocol modifications for 4 sites. Nevertheless, shared methodology and imaging protocols enabled other centres to obtain images suitable for qualitative and quantitative analysis.
conclusionsStandardised WB-MRI protocols can be implemented and supported in prospective multi-centre clinical trials. Trial registration NCT03188172 clinicaltrials.gov; registration date 15th June 2017 https://clinicaltrials.gov/ct2/show/study/NCT03188172.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.